TrueWealth Advisors LLC Sells 24 Shares of Chemed Co. (NYSE:CHE)

TrueWealth Advisors LLC trimmed its stake in Chemed Co. (NYSE:CHE) by 5.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 396 shares of the company’s stock after selling 24 shares during the period. TrueWealth Advisors LLC’s holdings in Chemed were worth $238,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of CHE. GAMMA Investing LLC grew its holdings in Chemed by 34.4% during the second quarter. GAMMA Investing LLC now owns 86 shares of the company’s stock valued at $47,000 after purchasing an additional 22 shares during the period. American National Bank & Trust bought a new position in shares of Chemed during the 3rd quarter valued at approximately $61,000. EntryPoint Capital LLC increased its holdings in Chemed by 14.0% in the 1st quarter. EntryPoint Capital LLC now owns 147 shares of the company’s stock worth $94,000 after acquiring an additional 18 shares in the last quarter. Mather Group LLC. raised its stake in Chemed by 60.5% during the 2nd quarter. Mather Group LLC. now owns 183 shares of the company’s stock worth $99,000 after acquiring an additional 69 shares during the period. Finally, Quarry LP lifted its holdings in Chemed by 721.7% during the second quarter. Quarry LP now owns 189 shares of the company’s stock valued at $103,000 after purchasing an additional 166 shares in the last quarter. 95.85% of the stock is owned by institutional investors.

Insider Transactions at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $598.81, for a total value of $1,197,620.00. Following the sale, the chief executive officer now directly owns 103,735 shares in the company, valued at approximately $62,117,555.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director George J. Walsh III sold 200 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $577.95, for a total transaction of $115,590.00. Following the completion of the transaction, the director now directly owns 3,446 shares of the company’s stock, valued at approximately $1,991,615.70. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $598.81, for a total value of $1,197,620.00. Following the completion of the sale, the chief executive officer now directly owns 103,735 shares in the company, valued at approximately $62,117,555.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,144 shares of company stock valued at $3,002,419. 3.32% of the stock is currently owned by corporate insiders.

Chemed Price Performance

Shares of NYSE CHE opened at $531.68 on Monday. Chemed Co. has a 1 year low of $525.36 and a 1 year high of $654.62. The stock has a market cap of $8.00 billion, a PE ratio of 26.87, a price-to-earnings-growth ratio of 2.19 and a beta of 0.46. The firm has a fifty day moving average price of $585.30 and a 200-day moving average price of $567.98.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $5.64 EPS for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a net margin of 12.69% and a return on equity of 27.86%. The business had revenue of $606.18 million during the quarter, compared to analysts’ expectations of $612.22 million. During the same quarter in the previous year, the firm earned $5.32 earnings per share. Chemed’s revenue was up 7.4% on a year-over-year basis. On average, research analysts expect that Chemed Co. will post 22.41 EPS for the current year.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.